NYSEAMERICAN:PTN

Palatin Technologies Stock Forecast, Price & News

$0.61
0.00 (0.00 %)
(As of 06/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.61
$0.63
50-Day Range
$0.38
$0.78
52-Week Range
$0.38
$1.30
Volume999,206 shs
Average Volume4.30 million shs
Market Capitalization$140.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
30 days | 90 days | 365 days | Advanced Chart
Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.


Palatin Technologies logo

About Palatin Technologies

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

714th out of 2,100 stocks

Pharmaceutical Preparations Industry

350th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

Is Palatin Technologies a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Palatin Technologies stock.
View analyst ratings for Palatin Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Palatin Technologies?

Wall Street analysts have given Palatin Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Palatin Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for Palatin Technologies
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings results on Monday, May, 17th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.03). The biopharmaceutical company earned $0.09 million during the quarter.
View Palatin Technologies' earnings history
.

What price target have analysts set for PTN?

1 brokerages have issued twelve-month price objectives for Palatin Technologies' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Palatin Technologies' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 391.8% from the stock's current price.
View analysts' price targets for Palatin Technologies
or view top-rated stocks among Wall Street analysts.

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:
  • Dr. John K. A. Prendergast, Co-Founder & Independent Non-Exec. Chairman (Age 67, Pay $97.5k)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 59, Pay $867.62k)
  • Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 64, Pay $797.21k)
  • Burns McClellan, VP of Investor Relations
  • Mr. Stephen A. Slusher Esq., Chief Legal Officer

Who are some of Palatin Technologies' key competitors?

What other stocks do shareholders of Palatin Technologies own?

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.03%), Geode Capital Management LLC (0.72%), GWM Advisors LLC (0.06%), James Investment Research Inc. (0.06%), Bank of New York Mellon Corp (0.04%) and Virtu Financial LLC (0.03%). Company insiders that own Palatin Technologies stock include Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills.
View institutional ownership trends for Palatin Technologies
.

Which major investors are selling Palatin Technologies stock?

PTN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Virtu Financial LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Palatin Technologies
or view top insider-selling stocks.

Which major investors are buying Palatin Technologies stock?

PTN stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, GSA Capital Partners LLP, CIBC Private Wealth Group LLC, UBS Group AG, GWM Advisors LLC, and James Investment Research Inc.. Company insiders that have bought Palatin Technologies stock in the last two years include Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr, and Stephen T Wills.
View insider buying and selling activity for Palatin Technologies
or or view top insider-buying stocks.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.61.

How much money does Palatin Technologies make?

Palatin Technologies has a market capitalization of $140.33 million and generates $120,000.00 in revenue each year. The biopharmaceutical company earns $-22,430,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Palatin Technologies have?

Palatin Technologies employs 20 workers across the globe.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is www.palatin.com.

Where are Palatin Technologies' headquarters?

Palatin Technologies is headquartered at 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.